Comparison of the disposition and in vitro metabolism of 4-vinylcyclohexene in the female mouse and rat.
4-Vinylcyclohexene (VCH) is a chemical to which humans are exposed in the rubber industry. A chronic carcinogenicity bioassay conducted by the National Toxicology Program showed that oral administration of VCH induced tumors in the ovaries of mice but not in those of rats. The hypothesis tested was that the species and organ specificity of VCH toxicity was due to differences in the disposition of VCH between the female rat and mouse. Therefore, the disposition of a single oral dose of 400 mg/kg [14C]VCH was studied in female B6C3F1 mice and Fischer 344 rats. Mice eliminated greater than 95% of the dose in 24 hr, whereas rats required 48 hr to eliminate greater than 95% of the dose. The major routes of excretion of [14C]VCH-derived radioactivity were in the urine (50-60%) and expired air (30-40%). No evidence was obtained to indicate that the ovaries of either species retained VCH as a parent compound or as radioactive equivalents. A dramatic difference was observed between the rat and mouse in the appearance of a monoepoxide of VCH in blood from 0.5 to 6 hr after VCH administration (800 mg/kg, ip). VCH-1,2-epoxide was present in the blood of mice with the highest concentration at 2 hr (41 nmol/ml). The blood concentration of VCH-1,2-epoxide in rats was less than 2.5 nmol/ml at all times examined. VCH-7,8-epoxide was not present in the blood of either species at the level of detection. These findings were supported by in vitro studies of VCH epoxidation by liver microsomes. The rate of epoxidation of VCH (1 mM) to VCH-1,2-epoxide was 6.5-fold greater in mouse liver microsomes than that in rat liver microsomes. The species difference in the rate of epoxide formation by the liver may be an important factor in the species difference in susceptibility to VCH-induced ovarian tumors.
Smith
B J
BJ
Department of Pharmacology and Toxicology, College of Pharmacy, University of Arizona, Tucson 85421.
Carter
D E
DE
Sipes
I G
IG
D000284:Administration, Oral; D000818:Animals; D002250:Carbon Radioisotopes; D002273:Carcinogens / Q000378:metabolism; D003510:Cyclohexanes / Q000008:administration & dosage / Q000097:blood / Q000378:metabolism / Q000493:pharmacokinetics*; D053138:Cyclohexenes; D005260:Female; D051379:Mice; D008815:Mice, Inbred Strains / Q000378:metabolism*; D008862:Microsomes, Liver / Q000378:metabolism; D010051:Ovarian Neoplasms / Q000139:chemically induced; D051381:Rats; D011916:Rats, Inbred F344 / Q000378:metabolism*; D013045:Species Specificity; D014018:Tissue Distribution; D014753:Vinyl Compounds / Q000097:blood
D002250:Carbon Radioisotopes; D002273:Carcinogens; D003510:Cyclohexanes; D053138:Cyclohexenes; D014753:Vinyl Compounds; C013733:4-vinylcyclohexene; C012606:4-vinyl-1-cyclohexene dioxide